Two classes of p38α MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes

Bioorganic & Medicinal Chemistry Letters
2005.0

Abstract

Two new classes of diphenylether inhibitors of p38alpha MAP kinase are described. Both chemical classes are based on a common diphenylether core that is identified by simulated fragment annealing as one of the most favored chemotypes within a prominent hydrophobic pocket of the p38alpha ATP-binding site. In the fully elaborated molecules, the diphenylether moiety acts as an anchor occupying the deep pocket, while polar extensions make specific interactions with either the adenine binding site or the phosphate binding site of ATP. The synthesis, crystallographic analysis, and biological activity of these p38alpha inhibitors are discussed.

Knowledge Graph

Similar Paper

Two classes of p38α MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes
Bioorganic & Medicinal Chemistry Letters 2005.0
The design and synthesis of novel α-ketoamide-based p38 MAP kinase inhibitors
Bioorganic & Medicinal Chemistry Letters 2008.0
Targeting the Hinge Glycine Flip and the Activation Loop: Novel Approach to Potent p38α Inhibitors
Journal of Medicinal Chemistry 2012.0
Optimization of α-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site
Bioorganic & Medicinal Chemistry Letters 2010.0
Dibenzosuberones as p38 Mitogen-Activated Protein Kinase Inhibitors with Low ATP Competitiveness and Outstanding Whole Blood Activity
Journal of Medicinal Chemistry 2013.0
From Five- to Six-Membered Rings:  3,4-Diarylquinolinone as Lead for Novel p38MAP Kinase Inhibitors
Journal of Medicinal Chemistry 2007.0
Synthesis, Biological Testing, and Binding Mode Prediction of 6,9-Diarylpurin-8-ones as p38 MAP Kinase Inhibitors
Journal of Medicinal Chemistry 2007.0
Biphenyl amide p38 kinase inhibitors 1: Discovery and binding mode
Bioorganic & Medicinal Chemistry Letters 2008.0
Design, Synthesis, and Biological Evaluation of Novel Type I<sup>1</sup>/<sub>2</sub> p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine
Journal of Medicinal Chemistry 2017.0
A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis
Bioorganic &amp; Medicinal Chemistry Letters 2004.0